{
    "organizations": [],
    "uuid": "8d0219e5691e9bf8ae4bc35b8864e6cfe5cc3b0c",
    "author": "",
    "url": "https://www.reuters.com/article/brief-spark-therapeutics-enters-into-lic/brief-spark-therapeutics-enters-into-licensing-supply-agreement-for-investigational-voretigene-neparvovec-outside-u-s-idUSASB0C26G",
    "ord_in_thread": 0,
    "title": "BRIEF-Spark Therapeutics Enters Into Licensing, Supply Agreement For Investigational Voretigene Neparvovec Outside U.S.",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 14 PM / in 6 minutes BRIEF-Spark Therapeutics Enters Into Licensing, Supply Agreement For Investigational Voretigene Neparvovec Outside U.S. Reuters Staff 1 Min Read \nJan 24 (Reuters) - Spark Therapeutics Inc: \n* SPARK THERAPEUTICS ENTERS INTO A LICENSING AND SUPPLY AGREEMENT FOR INVESTIGATIONAL VORETIGENE NEPARVOVEC OUTSIDE THE U.S. \n* SPARK THERAPEUTICS INC - SPARK THERAPEUTICS TO RECEIVE $105 MILLION AS AN UPFRONT FEE UNDER AGREEMENT \n* SPARK THERAPEUTICS INC - CO ALSO ENTERED INTO A SEPARATE AGREEMENT TO MANUFACTURE AND SUPPLY INVESTIGATIONAL VORETIGENE NEPARVOVEC TO NOVARTIS \n* SPARK THERAPEUTICS INC - ELIGIBLE TO RECEIVE UP TO AN ADDITIONAL $65 MILLION IN CASH MILESTONE PAYMENTS \n* SPARK THERAPEUTICS INC - NO OTHER PROGRAMS IN SPARK THERAPEUTICSâ€™ PIPELINE ARE PART OF THIS AGREEMENT \n* SPARK THERAPEUTICS INC - CO IS ALSO ENTITLED TO RECEIVE ROYALTY PAYMENTS ON NET SALES OF INVESTIGATIONAL VORETIGENE NEPARVOVEC OUTSIDE U.S Source text for Eikon: Further company coverage:",
    "published": "2018-01-24T23:13:00.000+02:00",
    "crawled": "2018-01-24T23:28:03.002+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "minute",
        "therapeutic",
        "enters",
        "licensing",
        "supply",
        "agreement",
        "investigational",
        "voretigene",
        "neparvovec",
        "outside",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "spark",
        "therapeutic",
        "inc",
        "spark",
        "therapeutic",
        "enters",
        "licensing",
        "supply",
        "agreement",
        "investigational",
        "voretigene",
        "neparvovec",
        "outside",
        "spark",
        "therapeutic",
        "inc",
        "spark",
        "therapeutic",
        "receive",
        "million",
        "upfront",
        "fee",
        "agreement",
        "spark",
        "therapeutic",
        "inc",
        "co",
        "also",
        "entered",
        "separate",
        "agreement",
        "manufacture",
        "supply",
        "investigational",
        "voretigene",
        "neparvovec",
        "novartis",
        "spark",
        "therapeutic",
        "inc",
        "eligible",
        "receive",
        "additional",
        "million",
        "cash",
        "milestone",
        "payment",
        "spark",
        "therapeutic",
        "inc",
        "program",
        "spark",
        "therapeutic",
        "pipeline",
        "part",
        "agreement",
        "spark",
        "therapeutic",
        "inc",
        "co",
        "also",
        "entitled",
        "receive",
        "royalty",
        "payment",
        "net",
        "sale",
        "investigational",
        "voretigene",
        "neparvovec",
        "outside",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}